Please login to the form below

Not currently logged in
Email:
Password:

Sobi names Holly May VP of sales and marketing, US

She will work with the biopharma’s commercial and patient access teams

Holly MayRare disease firm Sobi has appointed Holly May as its new vice president of sales and marketing for the US.

May’s new role will see her lead the biopharma’s commercial team in bringing Sobi’s medicines to the country.

She will also collaborate with the operations and patient access team to ensure the medicines are accessible to as many appropriate patients and she will support the launch of new products in the US.

May said: “I have been privileged to work in the rare disease field, leading commercial teams in providing education to patients, caregivers and physicians around important rare disease issues.

“I look forward to applying my expertise to help Sobi bring its existing and future products to patients who need them.”

May has had more than 20 years’ experience in biopharmaceutical sales and marketing, with her most recent role serving as head of US marketing for Fabry disease and lysosmal storage disorders at Sanofi Genzyme.

Prior to her 17-year career at Sanofi, May held various sales positions at DuPont Pharmaceuticals and Endo.

Rami Levin, president of Sobi, North America, said: “As we look to increase our footprint specifically in North America, where more than 33 million patients are estimated to suffer from a rare disease, Holly’s experience will be incredibly valuable.”

30th January 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...